

Brilliant Violet 421™ anti-mouse CD3 Antibody

Catalog# / Size	100227 / 125 µL 100228 / 50 µg
Clone	17A2
Regulatory Status	RUO
Other Names	T cell antigen receptor complex, T3
Isotype	Rat IgG2b, κ
Description	CD3, also known as T3, is a member of the Ig superfamily and primarily expressed on T cells, NK-T cells, and at different levels on thymocytes during T cell differentiation. CD3 is composed of CD3ε, δ, γ and ζ chains. It forms a TCR complex by associating with TCR α/β or γ/δ chains. CD3 plays a critical role in TCR signal transduction, T cell activation, and antigen recognition by binding the peptide/MHC antigen complex

Product Details

Verified Reactivity	Mouse
Antibody Type	Monoclonal
Host Species	Rat
Immunogen	γδTCR-positive T-T hybridoma D1
Formulation	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation	The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421™ under optimal conditions.
Concentration	µg sizes: 0.2 mg/mL µL sizes: lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)
Storage & Handling	The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application	FC - Quality tested ICC - Verified
Recommended Usage	Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis . For immunofluorescent staining using the µg size, the suggested use of this reagent is ≤ 0.25 µg per million cells in 100 µl volume. For immunocytochemistry using the µl size, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application. Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd. Learn more about Brilliant Violet™. This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser	Violet Laser (405 nm)
Application Notes	Additional reported application (for relevant formats) include: spatial biology (IBEX) ^{1,2} .
Application References	

(PubMed link indicates BioLegend citation)

1. Radtke AJ, *et al.* 2020. *Proc Natl Acad Sci U S A.* 117:33455-65. (SB) [PubMed](#)
2. Radtke AJ, *et al.* 2022. *Nat Protoc.* 17:378-401. (SB) [PubMed](#)

Product Citations

1. Kalinina A, *et al.* 2021. *STAR Protoc.* 2:100368. [PubMed](#)
2. Schädlich IS, *et al.* 2022. *iScience.* 25:104470. [PubMed](#)
3. John S, *et al.* 2020. *Sci Rep.* 10:11377. [PubMed](#)
4. Chukkapalli S, *et al.* 2015. *Pathog Dis.* 73:9. [PubMed](#)
5. Baptista AP *et al.* 2019. *Immunity.* 50(5):1188-1201. [PubMed](#)
6. Lee H, *et al.* 2020. *Cell Metabolism.* 31(4):822-836. [PubMed](#)
7. Piepke M, *et al.* 2021. *J Neuroinflammation.* 18:265. [PubMed](#)
8. Chen J, *et al.* 2022. *Nat Commun.* 13:6759. [PubMed](#)
9. Findlay EG, *et al.* 2019. *Oncoimmunology.* 8:1608106. [PubMed](#)
10. Go DM, *et al.* 2021. *Cell Mol Gastroenterol Hepatol.* 12:715. [PubMed](#)
11. Montes de Oca R, *et al.* 2021. *Mol Cancer Ther.* 20:1941. [PubMed](#)
12. Almshayakhchi R, *et al.* 2021. *Front Oncol.* 11:636977. [PubMed](#)
13. Royzman D, *et al.* 2022. *Front Immunol.* 13:1012647. [PubMed](#)
14. Bertocchi A, *et al.* 2021. *Cancer Cell.* 39(5):708-724.e11. [PubMed](#)
15. Chao CC, *et al.* 2020. *Cell.* 179(7):1483-1498.e22. [PubMed](#)
16. Britton GJ *et al.* 2019. *Immunity.* 50(1):212-224. [PubMed](#)
17. Jenkins RW, *et al.* 2018. *Cancer Discov.* 8:196. [PubMed](#)
18. Trenevskaa I, *et al.* 2021. *PLoS One.* 16:e0249967. [PubMed](#)
19. Emgård J, *et al.* 2018. *Immunity.* 48:419. [PubMed](#)
20. Glaser AK, *et al.* 2019. *Nat Commun.* 10:2781. [PubMed](#)
21. Jackstadt R, *et al.* 2019. *Cancer Cell.* 36:319. [PubMed](#)
22. Cameron G, *et al.* 2015. *J Immunol.* 195: 4604 - 4614. [PubMed](#)
23. Telford W, *et al.* 2017. *Cytometry A.* 91:314. [PubMed](#)
24. Elahi S, *et al.* 2020. *Stem Cell Res.* 43:101710. [PubMed](#)
25. Chen G, *et al.* 2021. *Sci Adv.* 7:eabg5686. [PubMed](#)
26. Solaymani-Mohammadi S, *et al.* 2016. *J Leukoc Biol.* 99: 475 - 482. [PubMed](#)
27. Chukkapalli S, *et al.* 2015. *PLoS One.* 10: 0143291. [PubMed](#)
28. Jin C, *et al.* 2019. *Cell.* 176:998. [PubMed](#)
29. Hasegawa T, *et al.* 2020. *Sci Rep.* 10:13480. [PubMed](#)
30. Hu Z, *et al.* 2020. *PLoS One.* 15:e0228339. [PubMed](#)
31. Zhu D, *et al.* 2017. *Stem Cell Res Ther.* 0.511805556. [PubMed](#)
32. Bristow CL, *et al.* 2021. *Front Oncol.* 11:739080. [PubMed](#)
33. Cartwright ANR, *et al.* 2021. *Cancer Immunol Res.* 9:470. [PubMed](#)
34. Royzman D, *et al.* 2019. *Front Immunol.* 10:633. [PubMed](#)
35. Heil J, *et al.* 2021. *Nat Commun.* 12:6963. [PubMed](#)
36. Kunishita Y, *et al.* 2020. *Front Immunol.* 11:98. [PubMed](#)
37. Fleskens V, *et al.* 2019. *Cell Rep.* 26:3600. [PubMed](#)
38. Tummala G, *et al.* 2021. *Invest Ophthalmol Vis Sci.* 62:41. [PubMed](#)
39. Henkle TR, *et al.* 2021. *Cancer Res.* 81:4560. [PubMed](#)
40. Chow AK, *et al.* 2021. *Cellular and Molecular Gastroenterology and Hepatology.* [PubMed](#)

RRID

AB_10900227 (BioLegend Cat. No. 100227)
AB_2562553 (BioLegend Cat. No. 100228)

Antigen Details

Structure	Ig superfamily, CD3/TCR, 20 kD
Distribution	Thymocytes (differentiation dependent), mature T cells, NK-T cells
Function	Antigen recognition, TCR signal transduction, T cell activation
Ligand/Receptor	Peptide antigen/MHC-complex
Antigen References	<ol style="list-style-type: none">1. Barclay A, <i>et al.</i> 1997. <i>The Leukocyte Antigen FactsBook</i> Academic Press.2. Davis MM. 1990. <i>Annu. Rev. Biochem.</i> 59:475.3. Weiss A, <i>et al.</i> 1994. <i>Cell</i> 76:263.
Gene ID	12502

Related Protocols


[Cell Surface Flow Cytometry Staining Protocol](#)

[Immunocytochemistry Staining Protocol](#)


Other Formats

FITC anti-mouse CD3, PE anti-mouse CD3, Purified anti-mouse CD3, Alexa Fluor® 647 anti-mouse CD3, Alexa Fluor® 488 anti-mouse CD3, Pacific Blue™ anti-mouse CD3, Alexa Fluor® 700 anti-mouse CD3, PerCP/Cyanine5.5 anti-mouse CD3, PE/Cyanine7 anti-mouse CD3, APC/Cyanine7 anti-mouse CD3, Brilliant Violet 421™ anti-mouse CD3, Brilliant Violet 570™ anti-mouse CD3, Brilliant Violet 650™ anti-mouse CD3, Brilliant Violet 785™ anti-mouse CD3, Brilliant Violet 510™ anti-mouse CD3, APC anti-mouse CD3, Ultra-LEAF™ Purified anti-mouse CD3, Brilliant Violet 605™ anti-mouse CD3, Alexa Fluor® 594 anti-mouse CD3, Brilliant Violet 711™ anti-mouse CD3, Biotin anti-mouse CD3, PE/Dazzle™ 594 anti-mouse CD3, APC/Fire™ 750 anti-mouse CD3, Brilliant Violet 750™ anti-mouse CD3, TotalSeq™-A0182 anti-mouse CD3, TotalSeq™-B0182 anti-mouse CD3, Spark Blue™ 550 anti-mouse CD3, Spark NIR™ 685 anti-mouse CD3, TotalSeq™-C0182 anti-mouse CD3, APC/Fire™ 810 anti-mouse CD3, PE/Fire™ 640 anti-mouse CD3, Spark YG™ 570 anti-mouse CD3, PE/Fire™ 700 anti-mouse CD3, PE/Cyanine5 anti-mouse CD3, Spark Blue™ 574 anti-mouse CD3 Antibody, Spark Violet™ 423 anti-mouse CD3, PE/Fire™ 810 anti-mouse CD3, Spark Red™ 718 anti-mouse CD3

Product Data



C57BL/6 mouse splenocytes were stained with CD19 APC and CD3 (clone 17A2) Brilliant Violet 421™ (top) or rat IgG2b, κ Brilliant Violet 421™ isotype control (bottom).



C57BL/6 mouse splenocytes were fixed with 2% paraformaldehyde (PFA), and then stained with 5 μg/ml CD3 (clone 17A2) Brilliant Violet 421™ (blue) and 5 μg/ml CD19 (clone 6D5) Alexa Fluor® 647 (red) for 30 minutes at room temperature. The image was captured by 40X objective.

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

